NYSE:MEDMedifast Stock Price, Forecast & News

Medifast's stock was trading at $70.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MED shares have increased by 147.6% and is now trading at $174.42.
View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Medifast.

Medifast is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for Medifast.

Medifast will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Medifast Inc (NYSE:MED) issued its quarterly earnings data on Tuesday, May, 5th. The specialty retailer reported $1.93 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.33 by $0.60. The specialty retailer had revenue of $178.46 million for the quarter, compared to analyst estimates of $161.90 million. Medifast had a net margin of 10.41% and a return on equity of 65.66%.
View Medifast's earnings history.

Medifast declared a quarterly dividend on Tuesday, June 16th. Shareholders of record on Tuesday, June 30th will be paid a dividend of $1.13 per share on Thursday, August 6th. This represents a $4.52 annualized dividend and a yield of 2.59%. The ex-dividend date of this dividend is Monday, June 29th.
View Medifast's dividend history.

4 brokers have issued 12-month target prices for Medifast's shares. Their forecasts range from $86.00 to $164.00. On average, they expect Medifast's stock price to reach $113.33 in the next year. This suggests that the stock has a possible downside of 35.0%.
View analysts' price targets for Medifast.

Press coverage about MED stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medifast earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media coverage about the specialty retailer a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future.
View the latest news about Medifast.

Medifast saw a decrease in short interest in July. As of July 15th, there was short interest totaling 1,830,000 shares, a decrease of 39.2% from the June 30th total of 3,010,000 shares. Based on an average daily volume of 284,500 shares, the days-to-cover ratio is presently 6.4 days. Approximately 16.3% of the shares of the company are short sold.
View Medifast's Current Options Chain.

Some companies that are related to Medifast include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Prestige Consumer Healthcare (PBH), USANA Health Sciences (USNA), Inter Parfums (IPAR), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Boeing (BA), Mastercard (MA), Micron Technology (MU), AbbVie (ABBV), Adobe (ADBE), Paypal (PYPL) and Baidu (BIDU).

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (0.45%), Robeco Institutional Asset Management B.V. (0.40%), Chickasaw Capital Management LLC (0.26%), Mackay Shields LLC (0.14%), New York State Teachers Retirement System (0.14%) and Bridge City Capital LLC (0.14%). Company insiders that own Medifast stock include Carl E Sassano, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Michael A Hoer, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends for Medifast.

MED stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Bridge City Capital LLC, First Trust Advisors LP, Chickasaw Capital Management LLC, Matisse Capital, Nisa Investment Advisors LLC, Ingalls & Snyder LLC, and ARP Americas LP. Company insiders that have sold Medifast company stock in the last year include Michael C Macdonald, and Scott Schlackman.
View insider buying and selling activity for Medifast.

MED stock was bought by a variety of institutional investors in the last quarter, including Mackay Shields LLC, Robeco Institutional Asset Management B.V., Parallel Advisors LLC, Icon Advisers Inc. Co., Arizona State Retirement System, Spearhead Capital Advisors LLC, First Citizens Bank & Trust Co., and GW Henssler & Associates Ltd.. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard, Jeffrey J Brown, and Michael A Hoer.
View insider buying and selling activity for Medifast.

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MED stock can currently be purchased for approximately $174.42.

Medifast has a market capitalization of $2.05 billion and generates $713.67 million in revenue each year. The specialty retailer earns $77.92 million in net income (profit) each year or $5.96 on an earnings per share basis. Medifast employs 420 workers across the globe.

The official website for Medifast is www.medifast1.com.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]